New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Stem Cell Therapy Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Stem Cell Therapy Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities.
WASHINGTON -- An FDA advisory panel on Thursday will decide whether to recommend approval of the investigational cellular therapy remestemcel-L for treating children with graft-versus-host disease (GVHD) following stem cell transplantation. No drugs are currently approved for the treatment of steroid-refractory acute GVHD in children under age 12, and the Oncologic Drugs Advisory Committee (ODAC) will be asked to vote on whether the available data support remestemcel-L's efficacy for pediatric patients with steroid-refractory acute GVHD. In a morning session, ODAC will review issues surrounding the manufacturing of remestemcel-L, which is described by sponsor Mesoblast as a product "comprising culture-expanded mesenchymal stem cells [MSCs] derived from the bone marrow of an unrelated donor." Patients with GVHD experience sustained systemic immune activation, and remestemcel-L's proposed mechanism of action is the reduction of these inflammatory processes mediated by the immunomodulatory bioactivity of MSCs
As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.
NEWARK, Del. and SAN FRANCISCO, Aug
INTRODUCTION In recent years, a number of growth factors have been tested in clinical trials for a variety of therapeutic applications including bone regeneration and neovascularization of ischemic tissues. Despite early promising results, the results obtained in larger phase 2 trials have often not shown the expected benefit to patients (1, 2), with some having marked adverse effects (35). The Infuse bone graft, which consists of recombinant human bone morphogenetic protein-2 (rhBMP-2) soaked onto a collagen sponge at a dosage of 1.5 mg/ml, has received Food and Drug Administration approval for certain spinal, dental, and trauma indications and is in widespread clinical use
This article was originally published here Front Med. 2020 Aug 6. doi: 10.1007/s11684-020-0810-9
DULUTH, Ga., Aug. 6, 2020 /PRNewswire/ --More than 500 veterinary students from across the U.S., as well as animal health researchers and leaders from three dozen top veterinary schools, convened virtually this week for the Veterinary Summer Scholars Symposium and presentation of the annual Boehringer Ingelheim Research Awards for Graduate Veterinarians and Veterinary Students. This annual scientific colloquium normally conducted in person -- showcases research by veterinary students completing summer research internships
Avacta has extended its collaboration and license agreement with Daewoong Pharmaceutical Co and their South Korean joint venture AffyXell Therapeutics. They will develop stem cell treatments incorporating Avactas neutralising Affimer therapy for the treatment of seriously ill patients with Covid-19 and prepare for the rapid development of similar therapies for future global pandemics.
As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.
This article was originally published here Stem Cell Rev Rep.
Recent Comments